Malignancy and hypercoagulability: a two-way association revisited.
Increasing evidence is highlighting the relationship between malignancy and hypercoagulability as a bidirectional association. We herein share our experience with a patient in whom such an association may be entertained. The patient, who had a history of venous thromboembolism, presented to our care with manifestation of stroke. Extensive workup revealed that the patient carries prothrombotic mutations in the prothrombin and methylenetetrahydrofolate reductase genes. The patient, a non-smoker, was also diagnosed with non-small cell lung carcinoma. The possible association between the patient's malignancy and prothrombotic state are further discussed.
Aoun
Elie G
EG
Department of Internal Medicine, Division of Hematology & Oncology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon.
Musallam
Khaled M
KM
Abou-Ghazal
Mohamad
M
Taher
Ali T
AT
D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000209:etiology*; D005260:Female; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000209:etiology; D011516:Prothrombin / Q000235:genetics; D020521:Stroke; D019851:Thrombophilia / Q000150:complications / Q000209:etiology; D054556:Venous Thromboembolism / Q000150:complications / Q000209:etiology* / Q000235:genetics
D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)